Selank 10mg Peptide

Chemical diagram for Selank by Edgar181 (talk) – Own work, Public Domain, https://commons.wikimedia.org/w/index.php?curid=9559689

KEY SPECIFICATIONS

PRODUCT OVERVIEW

Selank is a synthetic heptapeptide analog of the endogenous immunomodulatory peptide Tuftsin, engineered for enhanced metabolic stability in laboratory research. The C-terminal Pro-Gly-Pro extension protects against rapid serum peptidase degradation, extending half-life and bioavailability in experimental models.

Selank demonstrates dual mechanisms: allosteric modulation of GABA-A receptors and inhibition of enkephalin-degrading enzymes. Preclinical studies reveal significant effects on neurochemical signaling, gene expression regulation, and neuroimmune interactions. BIONIX supplies Selank with ≥99% purity for neuropharmacological and neuroimmunological research applications.

MECHANISM OF ACTION

Selank engages cellular signaling through a multi-target mechanism. As a stabilized Tuftsin derivative (Thr-Lys-Pro-Arg), it retains immunomodulatory affinity while demonstrating enhanced enzymatic resistance against proteolytic degradation.

GABAergic Neurotransmission Modulation:

Selank functions as a positive allosteric modulator of GABA-A receptor complexes, enhancing [³H]GABA binding affinity:

Consequences in neuronal cultures: • Enhanced hyperpolarization of neuronal membranes
• Reduced neuronal firing rates
• Dampening of overexcited neural networks
• Non-cumulative interactions with benzodiazepine sites

Enkephalinase Inhibition:

Selank inhibits enkephalin-degrading enzymes, increasing endogenous enkephalin stability:

Key Finding: Studies in anxiety models demonstrated increased leu-enkephalin half-life (tau₁/₂) correlating with anxiolytic activity markers.

Neurotrophic Factor Influence: Research indicates Selank may influence BDNF expression in hippocampal regions—critical for neuronal survival, synaptic plasticity, emotion regulation, and memory consolidation.

Neurotransmitter System Effects:

Gene Expression Profiling: Rodent studies demonstrate Selank significantly affects mRNA levels encoding: • GABA transporters
• GABA-A receptor subunits
• Neurochemical signaling components
• Cytokines (IL-6) and chemokines
• Bcl6 gene (immune development)

Comparative Profile:

RESEARCH APPLICATIONS

Anxiolytic Research Models: Investigation of anxiety-related behaviors in preclinical models without sedative effects. Studies demonstrate attenuation of aversive signs in withdrawal models, increased tactile sensitivity thresholds, and reduction of anxiety-like behaviors in elevated plus maze tests—distinguishing it from benzodiazepine-class compounds.

Nootropic Research: Analysis of cognitive function through BDNF upregulation, neurotransmitter balance optimization, and enhanced attention, learning, and memory consolidation markers in laboratory models.

Gene Expression Studies: Transcriptional profiling examining how neuropeptide interventions modulate neuronal excitability at mRNA levels—focusing on GABA transporters and GABA-A receptor subunits in frontal cortex and hippocampus.

Immunomodulation Research: Investigation of immune function in spleen tissue models, analyzing cytokine expression (IL-6), chemokine production, and Bcl6 gene expression—highlighting neuroimmune interface interactions.

Electrophysiological Analysis: Tissue slice preparations characterizing allosteric GABA receptor modulations, mapping chloride ion channel kinetics under synthetic peptide influence.

Neurotransmitter Balance Studies: Research on serotonin, dopamine, and noradrenaline pathway modulation—examining vigilance, attention, and emotional regulation mechanisms.

ANALYTICAL VERIFICATION

BIONIX Selank undergoes comprehensive analytical characterization:

• HPLC Analysis: ≥99% purity confirmation via optimized chromatographic separation
• Mass Spectrometry (MS): Identity verification and molecular weight confirmation (751.9 g/mol)
• Sequence Confirmation: Thr-Lys-Pro-Arg-Pro-Gly-Pro validation
• Endotoxin Testing: Laboratory quality assurance
• Stability Assessment: Pro-Gly-Pro extension verification

Physical Characteristics:

DEVELOPMENT STATUS

Selank has distinct regulatory status by region:

• Russia: Approved for anxiety treatment; available as nasal spray formulation
• European Union: Not approved for clinical use; research compound only
• United States: Not FDA approved; research use only
• Research Status: Extensive preclinical studies; clinical data primarily from Russian studies
• Global Research: Ongoing investigations in neurological, immunological, and cognitive domains
• WADA Status: Research compound (check current prohibited list)

BIONIX Selank is supplied exclusively for laboratory research purposes—not for human therapeutic use, clinical administration, or diagnostic applications.

FREQUENTLY ENCOUNTERED INQUIRIES

What is Selank’s mechanism of action?
Selank operates through dual mechanisms: (1) positive allosteric modulation of GABA-A receptors, enhancing GABA binding and chloride conductance; (2) competitive inhibition of enkephalin-degrading enzymes (NEP, aminopeptidase N), increasing endogenous enkephalin stability. Additionally, research indicates effects on BDNF expression and neurotransmitter system modulation (serotonin, dopamine, noradrenaline).

How does Selank differ from Semax?
Both are Russian-developed heptapeptides with enhanced metabolic stability, but operate through distinct mechanisms. Selank targets GABA-A receptors and enkephalinase (anxiolytic/cognitive focus), while Semax primarily influences BDNF/TrkB pathways and neurogenesis (neuroprotective focus). Selank is a Tuftsin analog; Semax is an ACTH analog. Neither produces sedative effects observed with benzodiazepines.

What is the significance of the Pro-Gly-Pro extension?
The C-terminal Pro-Gly-Pro sequence provides exceptional stability against serum peptidases that degrade native Tuftsin within minutes. This structural enhancement extends half-life, improves bioavailability in experimental models, and enables precise long-term observations with reduced dosing frequency requirements.

What are the primary research applications?
Anxiolytic behavior models (without sedation), nootropic/cognitive function studies, GABAergic neurotransmission research, gene expression profiling of neurochemical receptors, immunomodulation and neuroimmune interface studies, and electrophysiological GABA receptor characterization. All applications limited to controlled laboratory environments.

What storage conditions are required?
Lyophilized powder requires -20°C storage for long-term stability (up to 24 months). Post-reconstitution, store at 2-8°C and use within 4 weeks. For extended storage of reconstituted solution, prepare aliquots and freeze at -20°C, avoiding repeated freeze-thaw cycles.

Is Selank approved for clinical use?
Selank is approved for anxiety treatment in Russia as a nasal spray formulation. It is not FDA or EMA approved and is available exclusively for laboratory research in the EU and USA. BIONIX supplies research-grade material for laboratory use only—not for human therapeutic application.

REFERENCES

• PMID: 26903870 — Selank affects GABAergic neurotransmission gene expression (Front Pharmacol, 2016)
• PMID: 11420065 — Inhibitory effect on enkephalin-degrading enzymes (Bull Exp Biol Med, 2001)
• PMID: 21831414 — Expression of inflammation-related genes under Selank (Regul Pept, 2011)
• Preclinical Studies — Anxiolytic effects and withdrawal model attenuation
• Neurochemical Research — Neurotransmitter system modulation mechanisms
• Gene Expression Studies — GABA transporter and receptor subunit mRNA analysis